Professor and doctoral supervisor at West China Hospital, Sichuan University. Graduated from the School of Pharmacy, West China University of Medical Sciences in 1982. Earned a Ph.D. in Pharmacy from Nagoya University, Japan. Recruited back to China by West China Hospital in 2001. Founder and former Chairwoman of Chengdu WestChina Haiki Pharmaceutical Technology Co., Ltd., and Chief Scientist. Founder and Chief Scientist of Chengdu Haifeng Biotechnology.

Expert reviewer for the National Major New Drug Creation Program, member of the Supervision and Evaluation Group of the National Major New Drug Creation Program, expert of the Guidelines Drafting Group of the National Major New Drug Creation Program, and project leader of the National Preclinical Safety Evaluation Platform for New Drugs. Chief Scientist of the National "863" Research and Development and Application Platform for Non-Human Primate Models of Major Human Diseases, and responsible expert of the Major New Drug Creation Laboratory Animal Research and Development Platform. Vice Chairwoman of the Special Expert Committee on Biomedicine of the All-China Federation of Returned Overseas Chinese.

Drafter of the project guidelines for the National Major New Drug Creation Achievement Transfer and Transformation Pilot Demonstration Base, and head of the drafting group for the 14th Five-Year Plan for the Biological Economy of Sichuan Province.

Expert receiving the Special Government Allowance of the State Council, National March 8th Red Banner Pacesetter, Outstanding Contribution Award for the Development of Chinese Pharmacology and Toxicology, one of the 20 Outstanding Innovators and Entrepreneurs of the All-China Federation of Returned Overseas Chinese, and First Prize of the Sichuan Provincial Science and Technology Progress Award.